MRGPRX2/MRGPRB2 Antagonist Shows Promise for Rosacea Treatment in Mice

Rosacea is a prevalent, chronic inflammatory skin condition affecting millions globally, characterized by persistent facial erythema (redness), telangiectasias (visible blood vessels), and inflammatory papules and pustules. A critical pathogenic factor is the overexpression and dysregulation of the antimicrobial peptide LL-37, which triggers an aberrant immune response and promotes inflammation. Despite various available treatments, including topical and oral medications, many patients experience suboptimal outcomes or side effects, highlighting a significant unmet clinical need for more targeted and effective therapies. This pioneering study specifically addresses the knowledge gap by investigating whether pharmacologically antagonizing the Mas-related G protein-coupled receptors MRGPRX2 (in humans) and its murine ortholog MRGPRB2 (in mice) can effectively mitigate the severe LL-37-induced inflammation that underpins rosacea pathogenesis, thereby exploring a novel therapeutic pathway.